Clipping of news on Brazilian Culture, Law and Citizenship
06/12/2017
This article was translated by an automatic translation system, and was therefore not reviewed by people.
The drug Glimepiride, manufactured by the company Cimed, was suspended after notification of voluntary recall by the company.
By: Ascom / Anvisa
Posted: 06/06/2017 17:24 / Last Modified: 06/09/2017 17:27
Anvisa ordered the suspension of the distribution, sale and use of lot 1614707 of the generic drug Glimepiride, 4 mg, manufactured by Cimed Indústria de Medicamentos. The product is indicated for the treatment of non-insulin dependent diabetes mellitus (Type 2 or adult diabetes).
The manufacturer informed the Agency of the voluntary recall of the product after identifying that the packaging of the formulation was in presentation material different from that registered for the medicinal product.
Cimed will collect the existing stock in the market.
The suspension is described in RE 1.504 / 2017, published in the Official Gazette this Friday (9/6).
Want to know Anvisa news first hand? Follow us on Twitter @anvisa_oficial and Facebook @AnvisaOficial
Did you find any problems in this news? Send an e-mail to noticias@anvisa.gov.br
Source: Anvisa
To access the Anvisa website, click here.
Our news is removed in full from our partners' websites. For this reason, we can not change the content of these even in cases of typos.
This article was translated by an automatic translation system, and was therefore not reviewed by people.